PL1670432T3 - Formulacje aerozolowe obejmujące dwuwodny fumaran formoterolu, propelent, etanol i ewentualnie steroid, w których dwuwodny fumaran formoterolu ma zawartość wody wynoszącą 4,8-4,28% wagowego - Google Patents

Formulacje aerozolowe obejmujące dwuwodny fumaran formoterolu, propelent, etanol i ewentualnie steroid, w których dwuwodny fumaran formoterolu ma zawartość wody wynoszącą 4,8-4,28% wagowego

Info

Publication number
PL1670432T3
PL1670432T3 PL04769711T PL04769711T PL1670432T3 PL 1670432 T3 PL1670432 T3 PL 1670432T3 PL 04769711 T PL04769711 T PL 04769711T PL 04769711 T PL04769711 T PL 04769711T PL 1670432 T3 PL1670432 T3 PL 1670432T3
Authority
PL
Poland
Prior art keywords
formoterol fumarate
fumarate dihydrate
steroid
propellant
ethanol
Prior art date
Application number
PL04769711T
Other languages
English (en)
Inventor
Rudi Mueller-Walz
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of PL1670432T3 publication Critical patent/PL1670432T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04769711T 2003-10-09 2004-10-08 Formulacje aerozolowe obejmujące dwuwodny fumaran formoterolu, propelent, etanol i ewentualnie steroid, w których dwuwodny fumaran formoterolu ma zawartość wody wynoszącą 4,8-4,28% wagowego PL1670432T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0323684.1A GB0323684D0 (en) 2003-10-09 2003-10-09 Improvements in or relating to organic compounds
EP04769711.5A EP1670432B1 (en) 2003-10-09 2004-10-08 Aerosol formulations comprising formoterol fumarate dihydrate, a propellant, ethanol and optionally a steroid, where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight.
PCT/IB2004/003481 WO2005034911A1 (en) 2003-10-09 2004-10-08 Aerosol formulations comprising formoterol fumarate dihydrate, a propellant,ethanol and optionally a steroid,where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight

Publications (1)

Publication Number Publication Date
PL1670432T3 true PL1670432T3 (pl) 2014-08-29

Family

ID=29433594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04769711T PL1670432T3 (pl) 2003-10-09 2004-10-08 Formulacje aerozolowe obejmujące dwuwodny fumaran formoterolu, propelent, etanol i ewentualnie steroid, w których dwuwodny fumaran formoterolu ma zawartość wody wynoszącą 4,8-4,28% wagowego

Country Status (12)

Country Link
US (3) US20070256685A1 (pl)
EP (1) EP1670432B1 (pl)
CA (1) CA2540038C (pl)
CY (1) CY1115190T1 (pl)
DK (1) DK1670432T3 (pl)
ES (1) ES2472268T3 (pl)
GB (1) GB0323684D0 (pl)
HU (1) HUS2000052I1 (pl)
PL (1) PL1670432T3 (pl)
PT (1) PT1670432E (pl)
SI (1) SI1670432T1 (pl)
WO (1) WO2005034911A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
EP1372608B1 (de) * 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017093758A1 (en) * 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CA3037080C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
MX384545B (es) 2016-09-19 2025-03-14 Mexichem Fluor Sa De Cv Composicion farmaceutica
ES2957459T3 (es) 2016-09-19 2024-01-19 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
DE2914181C2 (de) * 1979-04-07 1982-06-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie
JPH01166505A (ja) 1987-12-22 1989-06-30 Teikoku Tsushin Kogyo Kk 電子部品の筺体及びその製造方法
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
JPH06135815A (ja) 1992-10-30 1994-05-17 Shiseido Co Ltd 経皮吸収抑制組成物
DE4321288A1 (de) 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
WO1995015151A1 (en) 1993-12-02 1995-06-08 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
JP3707107B2 (ja) 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
GB2337201B (en) 1997-01-30 2001-02-14 Alpenstock Holdings Ltd Haemostatic aerosol composition
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6033548A (en) * 1997-07-28 2000-03-07 Micron Technology, Inc. Rotating system and method for electrodepositing materials on semiconductor wafers
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
AU748867B2 (en) 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2001247123A1 (en) 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
EP1311294A2 (en) 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
NZ525054A (en) 2000-10-09 2004-11-26 3M Innovative Properties Co Medicinal aerosol formulations
EP1372608B1 (de) * 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
DK3384931T3 (da) * 2002-03-01 2019-09-16 Chiesi Farm Spa Superfin formoterolformulering
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
EP2319585A1 (en) 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium
WO2005004927A2 (en) 2003-07-12 2005-01-20 Jong-Hun Han An aromatic emitting apparatus for using cigarjack
AP2006003585A0 (en) 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918150D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation

Also Published As

Publication number Publication date
GB0323684D0 (en) 2003-11-12
SI1670432T1 (sl) 2014-07-31
US9895327B2 (en) 2018-02-20
US20140004052A1 (en) 2014-01-02
US20160310452A1 (en) 2016-10-27
EP1670432B1 (en) 2014-03-19
CY1115190T1 (el) 2017-01-04
US20070256685A1 (en) 2007-11-08
HUS2000052I1 (hu) 2020-12-28
WO2005034911A1 (en) 2005-04-21
PT1670432E (pt) 2014-06-23
ES2472268T3 (es) 2014-06-30
DK1670432T3 (da) 2014-06-10
CA2540038C (en) 2014-08-12
CA2540038A1 (en) 2005-04-21
EP1670432A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
HUS2000052I1 (hu) Formoterol-fumarát-dihidrátot, hajtóanyagot, etanolt és adott esetben szteroidot tartalmazó aeroszol készítmények, ahol a formoterol-fumarát-dihidrát víztartalma 4,8-4,28 tömeg%
SI1385494T1 (sl) Sestavki, ki vsebujejo formoterol in steroid, za dovajanje v pljuča
IL152448A0 (en) 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
AU2001281200A1 (en) Unsaturated oxime ethers and their use as fungicides
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
HUP0203728A3 (en) Aerosol composition comprising formoterol
IL163843A0 (en) Formoterol superfine formulation
AU2003231352A1 (en) Biocidal formulation and methods for the preparation thereof
WO2005034927A3 (en) Aerosol formulation comprising formoterol in suspension
IL209789A0 (en) Metabolites of 3-(2-dimethylaminomethyl-cyclohexyl)- phenol, pharmaceutical compositions comprising the same and uses thereof
MXPA03006526A (es) Composicion farmaceutica que contiene compuestos de aminoacetonitrilo y su uso para la preparacion de una composicion farmaceutica para el tratamiento de plagas endoparasitarias en animales.
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
MXPA03000624A (es) Composiciones y peliculas para la elaboracion de capsulas.
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
WO2007002823A3 (en) Formulations of conjugated estrogens and bazedoxifene
IL172180A (en) Use of at least one herb extract from the genus equisetum and at least one film forming agent for the preparation of topical compositions for treating onychoschizia
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
HUP0301024A3 (en) Synergystic fungicidal compositions and use thereof
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
AU4853801A (en) Medical combination comprising salmeterol and budesonide
IL174317A0 (en) Triterpene derivatives and pharmaceutical compositions containing the same
EP1857111A3 (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis
AU2003288974A8 (en) Compositions comprised of normal propyl bromide and 1,1,1,3,3-pentafluorobutane and uses thereof
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
HUP0302964A3 (en) Delta 1-pyrrolines, intermediates, preparation thereof and their use as pesticides